Recruiting

Cranberry Supplementation

Sponsor:

Laval University

Code:

NCT07460856

Conditions

Overweight/Obesity

Metabolic Syndrome

Insulin Resistance

Microbiota

Eligibility Criteria

Sex: All

Age: 25 - 70

Healthy Volunteers: Accepted

Interventions

Cranberry beverage

Placebo beverage

Study Details

Brief summary:

The consumption of plant-based foods, particularly berries, has been associated with improved health due to their high content of bioactive compounds. Among these, polyphenols-especially proanthocyanidins (PACs)-may offer protective effects against chronic diseases related to overweight and obesity. Cranberries are naturally rich in PACs and may positively influence metabolic health by modulating the gut microbiota. However, their specific effects on intestinal integrity and broader metabolic outcomes remain underexplored.

The primary aim of this study is to assess the effects of cranberry supplementation on glucose metabolism, insulin sensitivity, blood lipid levels, and the composition and function of the gut microbiota in overweight and obese individuals.

This randomized, double-blind, placebo-controlled, crossover clinical trial will include two 12-week intervention periods-one with a cranberry beverage and one with a placebo-separated by a 4-week washout period and preceded by a 2-week lifestyle stabilization phase. Participants will undergo comprehensive metabolic assessments (glucose control, insulin sensitivity, lipid profile), body composition analysis, gut microbiota profiling, and liver fat imaging (MRI in a subsample of female participants). Additional evaluations will include markers of inflammation, appetite regulation, intestinal health, and lifestyle factors.

Conditions

Overweight/Obesity

Metabolic Syndrome

Insulin Resistance

Microbiota

Study ID

NCT07460856

Start date

Jul 7, 2025

Status verified date

Mar, 2026

Completion date

Dec, 2026

Anticipated

Primary completion date

Dec, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 25 - 70

Healthy Volunteers: Accepted

Inclusion Criteria:

  • body mass index between 25 and 40 kg/m2
  • at least one of the following criteria: fasting plasma insulin >60 pmol/L, fasting glycemia between 5.5 and 6.9 mmol/L, glycated hemoglobin (HbA1c) level of 5.7- 6.4% and/or fasting triglyceride >1.35 mmol/L.

Exclusion Criteria:

  • to have aversion to cranberry products
  • regularly drinking alcohol (>2 glasses/day)
  • having a significant change in body weight in the past 3 months (±5% of their body weight) due to bariatric surgery or other conditions
  • taking medication which may affect the study outcomes (i.e. antidiabetic and/or cholesterol or lipid-lowering medications and/or glucocorticosteroid in supraphysiological doses and/or anti-obesity medications)
  • taking regular probiotics and prebiotics (including fruit/berry polyphenol supplements) in the past 3 months
  • having eating disorders
  • had undergone major surgery 3 months prior to the study or if they had one planned
  • if they had intestinal malabsorption, cirrhosis or chronic kidney disease
  • being pregnant, planning a pregnancy, or breastfeeding.

Study Design

Enrollment

73 participants

Anticipated

Allocation

Randomized

Intervention Model

Crossover

Primary purpose

Prevention

Interventions and Outcome Measures

Arms

experimental: Cranberry beverage

placebo comparator: Placebo beverage

Interventions

Cranberry beverage

Daily consumption of 240 ml of cranberry beverage for 12 weeks.

Placebo beverage

Daily consumption of 240 ml of placebo beverage for 12 weeks.

Primary outcome measure

  • Change in glucose homeostasis [ Time Frame: Pre and post each treatment (12 week/each) ]
  • Change in insulin secretion [ Time Frame: Pre and post each treatment (12 week/each) ]
  • Change in insulin secretion [ Time Frame: Pre and post each treatment (12 week/each) ]
  • Change in lipid profile [ Time Frame: Pre and post each treatment (12 week/each) ]

Central Contacts and Locations

Central contacts

Julie Marois, M.Sc.

1-418-656-5258julie.marois@fsaa.ulaval.ca

Locations

INAF, Université Laval

Recruiting

Québec, Quebec, Canada, G1V0A6

Contacts

Julie Marois, M.Sc.

1-418-656-5258julie.marois@fsaa.ulaval.ca

More Information

Sponsor

Laval University

Last update posted

Mar 10, 2026

Last verified

Mar, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Laval University on 2026-03-10.